Cyberonics unable to secure partner for therapy system approval
This article was originally published in Clinica
Executive Summary
Cyberonics has revealed that it has drawn a blank in its search for a partner for its anti-depression system. The news, announced on Oct 1, knocked 8% off the company's share price, which closed at $15.59.